| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fatima Abdullah AlRubaish, Nisha Gupta, Meng Zhu Shi, Stavroula Christopoulo. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism. BMJ case reports. vol 17. issue 5. 2024-05-21. PMID:38772867. |
she finally developed secondary adrenal insufficiency and was started on hydrocortisone replacement 4 weeks thereafter.this report highlights a case of immunotherapy-related hypophysitis with well-documented transient central hypercortisolism followed, within weeks, by profound secondary adrenal insufficiency. |
2024-05-21 |
2024-05-27 |
Not clear |
| Emmanouil Panagiotou, Sofia Ntouraki, Ioannis A Vathiotis, Maria Effrosyni Livanou, Athanasios Trimis, Georgios Evangelou, Andriani Charpidou, Konstantinos Syrigos, Melpomeni Pepp. Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730716. |
e-iraes presented at a median time of 4.1 months and included hypothyroidism (15.6%), hyperthyroidism (4.3%), adrenal insufficiency (0.4%), hypophysitis (0.4%), and diabetes mellitus (0.2%). |
2024-05-13 |
2024-05-27 |
Not clear |
| Sai-Ching Jim Yeung, Aiham Qdaisat, Jason J Bischof, Jeffrey M Caterino, Demetrios N Kyriacou, Christopher Coyne M. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors. The American journal of emergency medicine. 2024-05-05. PMID:38705758. |
a case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors. |
2024-05-05 |
2024-05-08 |
Not clear |
| Hiroshi Iesaka, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Takashige Abe, Nobuo Shinohara, Tatsuya Atsum. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report. Medicine. vol 102. issue 51. 2023-12-22. PMID:38134115. |
this case report may provide useful insight to understanding the etiology of ici-induced hypophysitis, a severe irae leading to potentially fatal secondary adrenal insufficiency. |
2023-12-22 |
2023-12-25 |
Not clear |
| Ashen Fernando, Aastha Mittal, Rashid Cheem. Nothing Great Comes Without Its Risks: A Rare Case of Pembrolizumab-Induced Hypophysitis. JCEM case reports. vol 2. issue 1. 2023-12-20. PMID:38116159. |
reported endocrinopathies include thyroid dysfunction, insulin-deficient diabetes mellitus, primary adrenal insufficiency, and hypophysitis. |
2023-12-20 |
2023-12-23 |
Not clear |
| Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, Yinglai Huan. Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case. Endocrine oncology (Bristol, England). vol 2. issue 1. 2023-07-12. PMID:37435468. |
two important lessons may be gleaned from this case: (i) ssts can be normal in early cases of secondary adrenal insufficiency, for example, hypophysitis due to adrenal reserve and (ii) when there is mismatch between the clinical and biochemical presentation, the acth should be repeated using a different assay. |
2023-07-12 |
2023-08-14 |
Not clear |
| Joshua K Salabei, Dhaval Upadhyay, Sripal A Pada. Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma. HCA healthcare journal of medicine. vol 2. issue 5. 2023-07-10. PMID:37425126. |
pituitary dysfunction (hypophysitis) leading to secondary adrenal insufficiency, or primary adrenal insufficiency caused by immune checkpoint inhibitors, have been documented. |
2023-07-10 |
2023-08-14 |
Not clear |
| Simona Coniac, Mariana Cristina Costache Outas, Edvina-Elena Pirvu, Raluca-Ileana Patru, Estera Gainariu, Ciprian Aldea, Polixenia Georgeta Iorga, Mihaela Ambroci, Horia-Dan Liscu, Andreea-Iuliana Miron, Corin Badi. Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania. Diagnostics (Basel, Switzerland). vol 13. issue 10. 2023-05-27. PMID:37238273. |
from this cohort, 109 nsclc patients qualified for baseline endocrine estimation and 13 patients (11.9%) developed endocrine iraes, such as hypophysitis (4.5%), thyroid disorder (5.5%) and primary adrenal insufficiency (1.8%), with one or more endocrine glands being affected. |
2023-05-27 |
2023-08-14 |
Not clear |
| Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, Anupam Kotwa. TEST ARTICLE: Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network : JNCCN. 2023-04-11. PMID:37041011. |
test article: hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. |
2023-04-11 |
2023-08-14 |
Not clear |
| Frédérique Albarel, Thierry Brue, Frédéric Castinett. Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Annales d'endocrinologie. 2023-03-25. PMID:36965852. |
french guidelines on immunotherapy-related endocrine iraes were published in 2018, with a specific algorithm for hypophysitis and primary adrenal insufficiency (pai), based on clinical suspicion followed by biochemical and imaging evaluation, and are still relevant today. |
2023-03-25 |
2023-08-14 |
Not clear |
| Frédérique Albarel, Thierry Brue, Frédéric Castinett. Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Annales d'endocrinologie. 2023-03-25. PMID:36965852. |
here we present the general pathophysiological mechanisms of these toxicities, and discuss the incidence, diagnosis, treatment, progression, management and monitoring of pituitary and adrenal disorders in patients treated by immunotherapy, with emphasis on hypophysitis, which is much more frequent than pai with this type of molecule. |
2023-03-25 |
2023-08-14 |
Not clear |
| Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, Anupam Kotwa. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network : JNCCN. 2023-02-24. PMID:36828029. |
hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. |
2023-02-24 |
2023-08-14 |
Not clear |
| Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V Karamouzi. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers. vol 15. issue 2. 2023-01-21. PMID:36672324. |
endocrine dysfunctions can manifest as hypophysitis, thyroid dysfunction, hypoparathyroidism, insulin-deficient diabetes mellitus, and primary adrenal insufficiency. |
2023-01-21 |
2023-08-14 |
human |
| Xinyu Shen, Minglan Yang, Hua Xu, Huan Zhou, Liwei Wang, Jing M. Immunotherapy-Associated Hypophysitis Under Anti-PD1: Two Case Reports. Endocrine, metabolic & immune disorders drug targets. 2022-12-12. PMID:36503448. |
he was diagnosed with adrenal insufficiency secondary to immunotherapy-associated hypophysitis and received a physiological dose of glucocorticoids. |
2022-12-12 |
2023-08-14 |
human |
| Benjamin C Park, Seungyeon Jung, Jordan J Wright, Douglas B Johnso. Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge. The oncologist. 2022-10-26. PMID:36288471. |
a 33-year-old woman with recurrent metastatic melanoma with adrenal, pelvic, and inguinal metastases developed recurrent hypophysitis during treatment with ipilimumab and nivolumab which recurred with rechallenge >5 years later. |
2022-10-26 |
2023-08-14 |
Not clear |
| Xiaoying Han, Min Meng, Tiehong Zhang, Jiao Wang, Guanghui Huang, Yang Ni, Wenhong Li, Jianjian Dai, Xia Yang, Xin Y. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy. Journal of cancer research and therapeutics. vol 18. issue 5. 2022-10-07. PMID:36204895. |
case 1 was a 60-year-old male patient with non-small-cell lung carcinoma, who was diagnosed with central adrenal insufficiency associated with hypophysitis after 11 cycles of camrelizumab treatment (200 mg every 2 weeks). |
2022-10-07 |
2023-08-14 |
Not clear |
| Priyanka Majety, Anna Groysman, Virginia Seery, Meghan Shea, Runhua Ho. Monitoring Endocrine Complications of Immunotherapy: A Screening Tool. Cureus. vol 14. issue 7. 2022-08-17. PMID:35974849. |
results a total of 27 (n) participants responded to the initial survey and 14 (n) responded to the subsequent survey six months later. based on the initial survey, only a minority (26%) of respondents were comfortable diagnosing and managing (15%) immunotherapy-related adrenal dysfunction whereas more respondents were comfortable diagnosing (55%) and managing (56%) thyroid dysfunction. the majority (67%) of the respondents knew which immunotherapies commonly are implicated in hypophysitis but only 42% of them were aware of the next steps of its management. we noted a significant increase in self-reported comfort levels in diagnosing (p < 0.05) and managing (p < 0.05) adrenal disorders post-intervention. there was also a trend of improvement in participants' comfort levels regarding diagnosing and managing thyroid dysfunction, management of hypophysitis, and immunotherapies implicated in thyroid dysfunction but the changes did not reach statistical significance. there was no significant change in their knowledge regarding immunotherapies implicated in hypophysitis and natural history of thyroid dysfunction in this setting. in the six months following our intervention, 30% (n=21) of the patients referred to the endocrine clinic were for immune-related endocrinopathies compared to 19% (n=7) of patients over a similar duration before the intervention. data on the time between referral and endocrinology appointment was available for 16 out of the 21 patients and the mean (±sd) time to endocrine clinic appointment was 2.66 (±1.95) weeks. nine (43%) of the 21 referred patients were seen in endocrinology clinic within two weeks. |
2022-08-17 |
2023-08-14 |
human |
| Tadashi Mizukoshi, Hidenori Fukuoka, Yutaka Takahash. Immune checkpoint inhibitor-related hypophysitis. Best practice & research. Clinical endocrinology & metabolism. 2022-05-13. PMID:35562229. |
early diagnosis and appropriate treatment of ici-related hypophysitis are essential as it can manifest as a life-threatening condition due to an adrenal crisis. |
2022-05-13 |
2023-08-13 |
Not clear |
| M Atkinson, A J Lansdow. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best practice & research. Clinical endocrinology & metabolism. 2022-04-06. PMID:35382989. |
these include hypophysitis, thyroid disease, and autoimmune diabetes mellitus, and rarer endocrinopathies such as primary adrenal insufficiency, diabetes insipidus, parathyroid disease, autoimmune polyglandular syndrome, lipodystrophy, and acth-dependent cushing's syndrome. |
2022-04-06 |
2023-08-13 |
Not clear |
| Jenny Bischoff, Charlotte Fries, Alexander Heer, Friederike Hoffmann, Carsten Meyer, Jennifer Landsberg, Wiebke K Fensk. It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. Journal of the Endocrine Society. vol 6. issue 5. 2022-03-31. PMID:35356006. |
we report here 3 cases of different endocrine iraes, first manifesting with new-onset hyponatremia under ici therapy for malignant melanoma: one with primary adrenal insufficiency, one with hypophysitis, and one with autoimmune type 1 diabetes. |
2022-03-31 |
2023-08-13 |
Not clear |